once approved, page-104

I agree, a take over bid would be much higher after approval, it would also need to satisfy the majority of shareholders. GG would need to make a very attractive offer.

On the negative, bad news from the FDA and IMO GG along with a few would very likely put in a SOA that would likely get approved. This would be plan B.

If the FDA go with a full 6 month review, MSB would probably need a top up. The upcoming announcement from the FDA will very likely set the scene for CLBP or CHF as partnerships would provide the necessary capital. In the event of a two month review the partner would only need to put in a very modest upfront payment and MSB would retain high royalties, on the other hand 6 month review and we would see the reverse. GG would have significant power on these negotiations .

ET talks about a CR. Not necessarily as post approval sales will rapidly add around 50 million to the cash balance in meeting demand on back log of patients that have no alternative. A delay in approval, the above partnership deal would add substantially to the balance sheet.

Just one week before the FDA should make this announcement, it may come early.